PDCD1 and hepatocellular carcinoma: With the publishing of CheckMate 040, KEYnote-240, Keynote-224, and SHR-1210 (4–7), PD-1 inhibitors have been included in multiple guidelines at home and abroad and recommended as the second-line therapy for advanced HCC.